Comparison of late survival in patients with cardiogenic shock due to right ventricular infarction versus left ventricular pump failure following primary percutaneous coronary intervention for ST-elevation acute myocardial infarction.

This study compared late survival after primary percutaneous coronary intervention (PCI) in patients with cardiogenic shock due to right ventricular (RV) infarction versus left ventricular (LV) pump failure. Consecutive patients with ST-elevation myocardial infarction treated with primary PCI (n = 2,496) were prospectively enrolled in a registry from 1984 to 2004. Cardiogenic shock occurred before PCI in 189 patients (7.

Door-to-balloon time with primary percutaneous coronary intervention for acute myocardial infarction impacts late cardiac mortality in high-risk patients and patients presenting early after the onset of symptoms.

Objectives: The purpose of this study was to evaluate the impact of door-to-balloon time with primary percutaneous coronary intervention (PCI) on late cardiac mortality.

Background: The impact of door-to-balloon time on outcomes is controversial, and the impact on late mortality has not been studied.

Methods: Consecutive patients (n = 2,322) treated with primary PCI from 1984 to 2003 were prospectively identified and followed up for a median of 83 months.

Poor long-term patient and graft survival after primary percutaneous coronary intervention for acute myocardial infarction due to saphenous vein graft occlusion.

Primary percutaneous coronary intervention (PCI) for ST segment elevation myocardial infarction (STEMI) due to saphenous vein graft (SVG) occlusion has been associated with poor procedural results and poor short-term outcomes, but long-term graft patency and patient survival have not been evaluated. Consecutive patients (n = 2,240) with STEMI treated with primary PCI from 1984 to 2003 were followed for 6.6 years (median).

Importance of time-to-reperfusion in patients with acute myocardial infarction with and without cardiogenic shock treated with primary percutaneous coronary intervention.

Background: Time-to-treatment is important for survival in patients with acute myocardial infarction (AMI) treated with fibrinolytic therapy, but the importance of time-to-treatment with primary percutaneous coronary intervention (PCI) is controversial. Previous studies evaluating the importance of time-to-treatment with primary PCI have not analyzed patients with cardiogenic shock separately.

Methods: Consecutive patients with AMI (n = 1843) treated with primary PCI were prospectively enrolled in the LeBauer Cardiovascular Research Foundation Registry.

Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study.

Objectives: This study was designed to assess whether use of enoxaparin during percutaneous coronary intervention (PCI) increased bleeding compared with unfractionated heparin, in addition to background therapy with eptifibatide.

Background: Data supporting the benefits of enoxaparin and the glycoprotein IIb/IIIa inhibitor eptifibatide evolved in parallel. Information on combining these two classes of medications is limited.

Effect of treatment delay on outcomes in patients with acute myocardial infarction transferred from community hospitals for primary percutaneous coronary intervention.

Outcomes were evaluated in 1,841 consecutive patients with acute myocardial infarction treated with primary percutaneous coronary intervention from 1984 to 2000 comparing patients transferred from community hospitals (n = 680) with patients presenting locally (n = 1,161). Baseline variables were similar except transferred patients had fewer prior infarctions (13% vs 21%, p <0.001) and underwent less prior bypass surgery (2.